July 29, 2014
/PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet") today announced that its second quarter financial results will be released on
Tuesday, August 12, 2014
. Following the announcement, Egalet's management will host a live conference call and webcast at
8:30 am Eastern Time
to review the Company's financial and operating results and provide a general business update.
The live webcast and a replay may be accessed by visiting Egalet's
. Please connect to the Company's website a few minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, you may dial 1-877-870-4263 (U.S.) or 1-412-317-0790 (international) to listen to the conference call and ask for the "Egalet Earnings Call." Telephone replay will be available approximately two hours after the call.
Egalet's mission is to help ensure access to effective medications for individuals living with chronic pain while protecting physicians, families and communities from the burden of abuse. Prescription opioid abuse has reached epidemic levels in
the United States
, with 6.8 million current prescription drug abusers and drug abuse is now the leading cause of accidental death in
the United States
. With the majority of opioids abused in
the United States
originating from a prescription and most often coming from a friend or family, a safeguard against the unexpected is needed. Egalet is committed to bringing peace of mind to the patients and physicians it serves by offering abuse-deterrent pain medications. Using the proprietary Guardian™ Technology the Company has a pipeline of clinical-stage, opioid-based product candidates that are specifically designed to deter abuse by physical and chemical manipulation. The Guardian Technology is customized to resist specific routes of abuse that often occur with the underlying active pharmaceutical ingredient. The Company's lead program, Egalet-001, an abuse-deterrent, extended-release, oral morphine formulation, is in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. It was designed to resist common methods of abuse, including one of the most common routes for morphine via injection. With no abuse-deterrent formulations of morphine currently available, Egalet-001 which is in pivotal studies, if approved, could fill a significant unmet need in the marketplace. Egalet plans to file an NDA for this product candidate in the fourth quarter of 2014. Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation, is in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. Egalet-002 was designed to resist common methods of abuse, including crushing and snorting the most common route of abuse for oxycodone. Egalet plans to file an NDA for Egalet-002 in the first half of 2016. Egalet entered into a collaboration with Shionogi in November of 2013, to develop abuse-deterrent hydrocodone based products. Egalet's Guardian™ Technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles. Egalet has a strong IP position of 58 granted patents and is continually enhancing its proprietary position. Visit
for more information.